Impact of multimodal therapy on the survival of patients with newly diagnosed uterine carcinosarcoma.

Abstract

PURPOSE:

To investigate treatment outcomes of uterine carcinosarcoma (CS) patients who underwent complete surgical resection of all visible disease and platinum-based adjuvant chemotherapy (multimodal therapy).

MATERIALS AND METHODS:

The authors reviewed 127 uterine CS patients treated at this institution from 1990 to 2010. They operated 123 patients in clinical Stages 1-3, 97 of which underwent complete resection and systemic lymphadenectomy.

RESULTS:

A total of 97 patients (FIGO 2008: Stage 1 in 50 patients, Stage 2 in six, Stage 3 in 37, and Stage 4 in four) underwent surgical staging, 74 of which were administered five cycles (median) of platinum-based adjuvant chemotherapy. The median overall survival (OS) associated with multimodal therapy 50.6 months compared with 34.9 months incomplete multimodal therapy. After multimodal treatment, 32.9% (32/97) patients showed recurrence (24/32 hematogenous).

CONCLUSION:

Multimodal therapy increased survival among uterine CS patients, but the recurrence rate remained high. Further consideration of treatment options for uterine CS is required.

• Authors: H Machida, K Takahashi, H Nomura, M Matoda, K Omatsu, K Kato, K Umayahara, N Takeshima
• Journal: European journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 34 Issue 4 Pg. 291-5 ( 2013) ISSN: 0392-2936 [Print] Singapore
• PMID: 24020131 (Publication Type: Journal Article)

Topics

• Adult
• Aged
• Carcinosarcoma (mortality, pathology, therapy)
• Combined Modality Therapy
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local
• Neoplasm Staging
• Prognosis
• Uterine Neoplasms (mortality, pathology, therapy)